Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Executives from Pfizer Inc and Amazon.com see opportunities for working with U.S. health secretary nominee Robert F. Kennedy Jr to manage growing health risks in a warming world. Amazon ...

Gelfoam (Pfizer), Gelitacel (Gelita Medical), bone wax or cautery may be used to achieve hemostasis. Open wounds should be protected and mobile shell areas stabilized. If injuries are confined to ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino ...

Bonus Jun 12, 2000 Jun 28, 2000 May 25, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus--Jul 25, 1977 Bonus Ratio: 4 share(s) for every 5 shares held Bonus--Jul 25, 1972 Bonus Ratio: 2 ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD ...

Pfizer on Wednesday said it will promote Chris Boshoff to chief scientific officer and president of research and development as the giant drugmaker struggles to win back the faith of investors.

Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for lung cancer and obesity, adding to collaborations it formed with other Flagship startups earlier this year.

Pfizer said its chief oncology officer, Chris Boshoff, will head all of the company’s research and development efforts in addition to keeping his current duties overseeing the company’s ...

Pfizer PFE1.44%increase; green up pointing triangle elevated the executive in charge of its cancer-drugs business to oversee all of the drugmaker’s research and development, a crucial move at a ...